Bio Techne's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Bio Techne (TECH) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Bio Techne vs Its Competitors
- TTM: Trailing 12-month revenue of 1,214M vs 128,576M combined for tracked competitors (0.9% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+5.8% annualized vs trailing 12 months), vs holding steady (+1.5%) for its tracked peer group.
- Growth: Bio Techne generated 1.1% revenue growth year over year in Q4 2026, vs 7.3% for its tracked competitors combined.
- Profitability: Its 17.0% net margin compares with 4.0% for the peer group.
- Peer revenue share: Bio Techne accounted for 1.0% of combined revenue among its tracked peer group, down from 1.0% a year earlier.
- Peer differentiation: Revenue per employee of $0.40M compares with $0.55M for the peer group (0.7x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
TECH Sales vs. its Competitors, Q4 2026
Bio Techne reported revenue growth of 1.06 % year on year in Q4 2026, below its competitors' combined revenue growth of 7.32 %.
With a net margin of 17.01 %, Bio Techne achieved higher profitability than its competitors (4.03 %).
Bio Techne generated 0.98 % of the combined sales of its peer group, down from 1.04 % a year earlier.
Bio Techne vs. its Competitors, Q4 2026
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Bio Techne and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Bio techne Corp | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (7) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (3) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Bio Techne's competitor groups requires a Commercial License.
For context: the Biotechnology & Pharmaceuticals industry grew revenue 20.7% year over year, combined, vs 1.1% for Bio Techne. Bio Techne's share of combined industry revenue moved from 0.87% to 0.73%, a loss of 0.14 percentage points.
Bio Techne's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Bio techne Corp | Yes | No | No | No |
| Competitors combined (8) | ||||
| High-Confidence Competitors (10) | ||||
| Similar Growth & Profitability (8) | 100.00 % (8 of 8) | 87.50 % (7 of 8) | 0.00 % (0 of 8) | 37.50 % (3 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
TECH Stock Performance relative to its Competitors
TECH Stock Performance relative to High-Confidence Competitors
TECH Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Twist Bioscience Corporation | 282.9% | Outperformed |
| 2 | Illumina Inc | 282.9% | Outperformed |
| 3 | Merck and Co Inc | 282.9% | Outperformed |
| 4 | Repligen Corp | 282.9% | Outperformed |
| 5 | Thermo Fisher Scientific Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Bio Techne's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Bio Techne's Comment on Competition and Industry Peers
Publicly Traded Peers of Bio techne Corp
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Bio techne Corp | 11,381.58 | 1,213.87 |
| Merck and Co Inc | 370,191.25 | 66,569.00 |
| Thermo Fisher Scientific Inc | 250,948.11 | 46,336.00 |
| Agilent Technologies inc | 49,765.52 | 7,372.00 |
| Illumina Inc | 41,899.05 | 4,493.00 |
| Twist Bioscience Corporation | 11,454.69 | 431.80 |
| SUBTOTAL | 766,472.49 | 131,824.26 |
Sign in to see all competitors of Bio techne Corp.
Sources: Bio techne Corp's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Bio techne Corp versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Bio Techne's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Quanterix Corporation | Named by the company | 85% |
| Danaher | Named by the company | 85% |
| Molecular Devices | Named by the company | 85% |
| Thermo Fisher Scientific, Inc | Named by the company | 85% |
| Akoya Biosciences Inc | Named by the company | 85% |
| BD Biosciences | Named by the company | 85% |
| Meso Scale Discovery | Named by the company | 85% |
| Shimadzu | Named by the company | 85% |
| Abcam plc. | Named by the company | 85% |
| Luminex | Named by the company | 85% |
| PeproTech, Inc. | Named by the company | 85% |
| Waters | Named by the company | 85% |
| Mdxhealth Sa | Named by the company | 85% |
| Bio-Rad Laboratories | Named by the company | 85% |
| Millipore | Named by the company | 85% |
| Tecan BioTek | Named by the company | 85% |
| Agilent Technologies | Named by the company | 85% |
| Merck KGaA | Named by the company | 85% |
| PerkinElmer | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Bio Techne's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Bio Techne's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Bio techne Corp | Protein Sciences 72.65 % |
| Merck and Co Inc | Pharmaceutical segment 88.88 % |
| Thermo Fisher Scientific Inc | Clinical Research 19.98 % |
| Agilent Technologies inc | Agilent CrossLab 41.36 % |
| Illumina Inc | Sequencing 90.94 % |
| Twist Bioscience Corporation | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Bio Techne's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Bio techne Corp | 11,382 | 404,623 | 60,621 |
| Merck and Co Inc | 370,191 | 887,587 | 42,267 |
| Thermo Fisher Scientific Inc | 250,948 | 370,688 | 55,912 |
| Agilent Technologies inc | 49,766 | 407,293 | 79,558 |
| Illumina Inc | 41,899 | 3,510,156 | 644,531 |
| Twist Bioscience Corporation | 11,455 | 441,060 | -139,650 |
| PEERS TOTAL | 755,091 | 554,588 | 55,098 |
Bio Techne's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Bio techne Corp | US 53.80 % |
| Merck and Co Inc | EMEA 23.60 % |
| Thermo Fisher Scientific Inc | North America 51.27 % |
| Agilent Technologies inc | Americas 41.63 % |
| Illumina Inc | United States and Canada 56.34 % |
| Twist Bioscience Corporation | Americas 58.08 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Bio Techne's Position in Industry Market Structure
Market-capitalization share and concentration across all 159 companies in Bio Techne's industry classification, broader than the peer set above. Market cap in millions of $.Bio Techne ranks #0 of 159 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 1,320, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Amgen Inc | 227,218 | 25.72 % |
| 2 | Gilead Sciences Inc | 188,277 | 21.31 % |
| 3 | Moderna Inc | 81,799 | 9.26 % |
| 4 | Argenx Se | 63,476 | 7.19 % |
| 5 | Revolution Medicines Inc | 1,234 | 5.2% |
| 6 | Biogen Inc | 1,234 | 5.2% |
| 7 | Biontech Se | 1,234 | 5.2% |
| 8 | Exelixis Inc | 1,234 | 5.2% |
| 9 | Neurocrine Biosciences Inc | 1,234 | 5.2% |
| 10 | Halozyme Therapeutics Inc | 1,234 | 5.2% |
| 0 | Bio techne Corp | 11,372 | 0.00 % |
Market cap and industry share for the rest of Bio Techne's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-09-29.
Bio Techne's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Biotechnology & Pharmaceuticals industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (93 companies). See the full Biotechnology & Pharmaceuticals industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 65.83 % | 68.46 % (avg) | -2.6 pp |
| Operating Margin | 20.75 % | industry median | +225.7 pp |
| EBITDA Margin | 38.98 % | -0.94 % (avg) | +39.9 pp |
| Capital Intensity (Capex / Revenue) | - | 6.74 % (avg) | - |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Bio Techne's Valuation vs Competitive Position
Valuation multiples vs the Biotechnology & Pharmaceuticals industry average (93 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Biotechnology & Pharmaceuticals industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | 51.7x | 26.7x | +25.0x |
| EV / EBITDA | 19.9x | 21.3x | -1.4x |
| P/B | 4.6x | 5.1x | -0.5x |
| Return on Equity | 9.01 % | industry aggregate | 12.44 % |
| Return on Invested Capital | 5.71 % | -6.17 % (avg) | 11.88 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Bio Techne's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | 13.74 % | 9.24 % | 7.29 % | 28.86 % | 8.76 % | 2.11 % | 4.55 % | 1.62 % |
| Operating Margin | 21.32 % | 21.17 % | 23.43 % | 25.52 % | 26.36 % | 23.49 % | 15.64 % | 9.63 % |
| Return on Invested Capital | 5.31 % | 5.21 % | 5.52 % | 6.96 % | 7.60 % | 6.10 % | 4.10 % | 2.71 % |
| P/E | 15.7x | 10.9x | 71.5x | 89.9x | 29.3x | 62.2x | 75.0x | 122.7x |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Bio Techne's Strategic Group Map
Every company in Bio Techne's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Bio Techne is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Bio Techne's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 1,320 (see Industry Market Structure & Concentration above) |
| Supplier Power | Not covered on this page | See Bio Techne's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Bio Techne's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Bio Techne's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Bio Techne falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Bio Techne's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Operating margin 225.7 points above the industry median.
- Return on equity 12.4 points above the industry aggregate.
- Latest-quarter revenue run-rate is accelerating (+5.8% annualized vs trailing 12 months).
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
No rule matched.
Opportunities
- Industry revenue growing at a healthy 10.0% median pace.
- A meaningful share of tracked competitors (50.00 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Bio Techne's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Bio techne Corp | 1.23 | 4.16 | 0.13 |
| Merck and Co Inc | 0.40 | 1.46 | 1.01 |
| Thermo Fisher Scientific Inc | 0.32 | 1.62 | 0.78 |
| Agilent Technologies inc | 0.77 | 2.02 | 1.02 |
| Illumina Inc | - | 1.74 | 0.75 |
| Twist Bioscience Corporation | 1.43 | 3.10 | 0.03 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Bio Techne's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Bio techne Corp | Q2 2026 | +1.1 % | - |
| Merck and Co Inc | Q2 2026 | +5.1 % | - |
| Thermo Fisher Scientific Inc | Q2 2026 | +10.5 % | +7.6 % |
| Agilent Technologies inc | Q2 2026 | +8.1 % | +7.7 % |
| Illumina Inc | Q2 2026 | +9.4 % | -11.9 % |
| Twist Bioscience Corporation | Q2 2026 | +23.2 % | - |
| PEERS TOTAL | +7.2 % | -74.5 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Bio Techne's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Bio techne Corp | Q2 2026 | -7.7 % | +73.4 % |
| Merck and Co Inc | Q2 2026 | +23.6 % | +16.9 % |
| Thermo Fisher Scientific Inc | Q2 2026 | +142.5 % | +53.1 % |
| Agilent Technologies inc | Q2 2026 | -1.6 % | -22.3 % |
| Illumina Inc | Q2 2026 | +6.9 % | +33.3 % |
| Twist Bioscience Corporation | Q2 2026 | +24.9 % | +6.5 % |
Bio Techne's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Bio techne Corp | 7.12% | 7.61% | 9.01% |
| Merck and Co Inc | 2.42% | 3.24% | 6.59% |
| Thermo Fisher Scientific Inc | 6.36% | 7.71% | 13.37% |
| Agilent Technologies inc | 10.97% | 19.84% | 41.99% |
| Illumina Inc | 12.68% | 19.61% | 31.08% |
| Twist Bioscience Corporation | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Bio Techne's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Bio techne Corp | 63.03 | 9.38 |
| Merck and Co Inc | 120.87 | 5.56 |
| Thermo Fisher Scientific Inc | 36.41 | 5.42 |
| Agilent Technologies inc | 34.68 | 6.75 |
| Illumina Inc | 51.28 | 9.33 |
| Twist Bioscience Corporation | - | 26.53 |
| PEERS AVERAGE | 58.25 | 5.81 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.